DMRA
Damora Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$30.06
+7.36%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-50.9%
Return on equity
-48.3%
Return on assets
-52.4%
Return on invested capital
0.00x
Asset turnover
-$6.7M
Cash from operations
$8.76
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026